Ohio is currently home to 3309 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760
Recruiting
The goal of this study is to evaluate V940 plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of completely resected (R0) Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: University Hospitals Cleveland Medical Center ( Site 0023), Cleveland, Ohio
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
NCT06072482
Recruiting
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/19/2024
Locations: Stat Research, Miamisburg, Ohio
Conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Register for Updates
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252
Recruiting
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/19/2024
Locations: Velocity Clinical Research, Mt. Auburn, Cincinnati, Ohio
Conditions: Type 2 Diabetes, Obesity
Register for Updates
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
NCT06029270
Recruiting
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the co... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio
Conditions: Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Register for Updates
Safety and Tolerability of GTX-104 Compared With Oral Nimodipine in Patients With aSAH
NCT05995405
Recruiting
The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Aneurysmal Subarachnoid Hemorrhage (aSAH)
Register for Updates
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
NCT05983770
Recruiting
This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/19/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Kidney Transplant Rejection
Register for Updates
A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria
NCT05967806
Recruiting
The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatment choices for this patient group in different regions.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/19/2024
Locations: Research Site, Maumee, Ohio
Conditions: Renal Disease
Register for Updates
Project 3: ACHIEVE- CHD
NCT05918380
Recruiting
This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health Inequities by Early PreVEntion in the GREAT LakEs Region) Center (IRB 100221MP2A), the purpose of which is to reduce cardiometabolic health disparities and downstream Black-White lifespan inequality in two cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center will involve three separate but related projects that aim to mitigate health disparities in risk factor control for three chronic conditions... Read More
Gender:
All
Ages:
Between 40 years and 75 years
Trial Updated:
06/19/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Coronary Heart Disease
Register for Updates
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
NCT05886049
Recruiting
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has changes in the NPM1 gene or MLL/KMT2A gene. SNDX-5613 blocks signals passed from one molecule to another inside cancer cells that are needed for cancer cell survival. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/19/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation
Register for Updates
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
06/19/2024
Locations: Bexley Dermatology Research, Bexley, Ohio
Conditions: Atopic Dermatitis
Register for Updates
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
NCT05882045
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Obesity, Cardiovascular Diseases
Register for Updates
A Study of DB-OTO, an Adeno-associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations
NCT05788536
Recruiting
Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat children who have hearing loss due to changes in the otoferlin gene. The purpose of this study is to: Learn about the safety of DB-OTO Determine how well DB-OTO is tolerated (does not cause ongoing discomfort) Evaluate the efficacy of DB-OTO (how well DB-OTO works)
Gender:
All
Ages:
17 years and below
Trial Updated:
06/19/2024
Locations: Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Register for Updates